Back to catalogue
№ 126 33 filings · 2021-07-13 → 2026-07-03

CRANEWARE PLC

CRW
Health Care Share price 1,374p Market cap £477m Overall fit 505 /1000

Genuine vertical-SaaS operating leverage and a fair-to-cheap price with net-cash downside protection, offset by indirect AI exposure and a freshly stalled growth trajectory with live regulatory risk to the primary growth engine.

Fair value range 1,150p–1,500p Mid case · £453m
Absolute upside -5.1% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean SaaS revenue recognition and disclosure; audited by PwC
  • Fortress net cash balance sheet with strategic-buyer floor from rejected £26.50 offer
  • High customer retention (>90%) and multi-year contracted ARR of $184m
Limits the call
  • FY26 profit warning reset growth narrative; too early to distinguish timing vs structural in 340B
  • Regulatory overhang from 340B rebate pilot and pharma manufacturer supply restrictions
Methodology

Forward P/E multiple range, cross-checked EV/EBITDA

In one line · bull case

Moated healthcare-IT vertical SaaS with net cash and strong operating leverage, now available at a fair price after a growth stall that may prove partly cyclical.

In one line · biggest risk

The 340B revenue stream — recently the primary growth engine — is exposed to manufacturer supply restrictions and regulatory redesign that management cannot control.

Drivers
AI beneficiary 45 /100
Proprietary 200m-patient dataset and Microsoft partnership give real optionality, but AI is workflow enhancement rather than a new revenue line.
Operating leverage 78 /100
85% gross margin, largely fixed R&D base; margins expanded 200bps H1 FY26 despite modest growth.
Earnings vs expectations 40 /100
Three years of in-line-to-beat prints broken by a material FY26 miss in July 2026.
Growth momentum 35 /100
Just guided FY26 revenue flat vs FY25 vs prior double-digit ambition; ARR growth of 4% below revenue growth.
Moat 65 /100
Deep switching costs, unique data, and regulatory expertise; 340B rule-making creates a structural vulnerability.
Earnings quality 75 /100
Clean SaaS accounting, 85% rolling cash conversion, transparent adjusted vs statutory reconciliation.
Management quality 65 /100
Founder CEO with 9%+ personal stake and buying at 750p exercise price; recent forecasting credibility dented.
Cyclicality 25 /100
Recurring SaaS with high retention but 340B introduces quasi-regulatory-cyclical volatility.
Leverage 15 /100
Net cash of $17.5m plus $176m undrawn facilities — genuine fortress balance sheet.
Value-trap signals · 3
  • Guidance credibility damaged by January-to-July 2026 downgrade sequence
  • Regulatory/manufacturer attack on the 340B economics that underpin the largest growth engine
  • Historically minimal new-customer share gains — growth relied on cross-sell into existing base

Craneware plc (CRW.L) — Research Note

Executive summary

Craneware is a vertical SaaS provider of financial and operational software (revenue integrity, chargemaster, 340B pharmacy compliance, cost intelligence) to ~40% of US hospitals, reporting in USD but listed on AIM in GBP. The operating trajectory across the period was one of transformation — the July 2021 acquisition of Sentry Data Systems doubled revenue and reshaped the group around a cloud "Trisus" platform, growth accelerated to 9% in FY25 with 30%+ EBITDA margins — but momentum broke in FY26 when a 340B trading update (3 July 2026) told the market FY26 would be "broadly in line with FY25" versus expectations of double-digit growth, driven by pharmaceutical manufacturers restricting 340B-priced drug supply. The single most important valuation point today is whether the FY26 340B slowdown is a temporary transmission-mechanism issue (management's view) or a permanent structural impairment to a business line that has been the primary growth engine — the market has already priced roughly half of the more bearish outcome, with shares down ~57% from FY26 highs.

Fair value estimate

Fair value range: 1,150p – 1,500p per share (£393m – £513m market cap)

Methodology: Multiple of forward earnings, cross-checked against EV/EBITDA. FY25 adjusted diluted EPS was 114.2 US cents (~85p at $1.35/£). Given the FY26 profit warning implies broadly flat FY25/FY26 profits, forward EPS is anchored around 85-90p. Applying a de-rated multiple range of 13x–17x (Craneware historically traded at 25-40x pre-warning; peer vertical SaaS with growth headwinds trade at 13-18x) yields 1,150p–1,500p.

Cross-check on EV/EBITDA: FY26E Adj EBITDA $65-67m (£48-50m). Enterprise value at midpoint fair value ≈ £440m, less net cash ~£13m ($17.5m net cash H1 FY26 2026-03 H1), = EV ~£425m, implying ~8.7x EV/EBITDA — reasonable for a de-rated vertical SaaS growing single-digits.

Compared to £415.6m current market cap: modest upside of ~+15% to midpoint (1,325p), fair-to-slightly-cheap.

Note: the June 2025 board rejected a £26.50 (2,650p) unsolicited approach 2025-09 FY25 results. That anchor point pre-dates the 340B warning and reflected a bull case that is no longer intact.

Sector context

ICB Health Care classification is accurate but understates the software-vertical-SaaS characterisation. Craneware is closer to a healthcare-IT operator than a pharma/services name. Quality/growth/leverage profile: gross margin 85%+ and net cash balance sheet are above sector peers; growth is now in line with mature healthcare-IT after the FY26 stall (previously above); leverage/quality profile clearly above typical AIM healthcare peers.

Listed peers: Veeva Systems (VEEV, US) — the closest analogue but larger and higher-growth; Definitive Healthcare (DH, US) — healthcare data SaaS; historic UK comparators (EMIS, Iris) have been taken private.

Investment thesis

  • Deep customer entrenchment with high NRR and quality recurring economics. 40% of US hospitals as customers, 15th Best-in-KLAS ranking for Trisus Chargemaster, customer retention >90% on all measures, NRR of 103% (H1 FY26 rolling 12m), ARR $184.2m. Land-and-expand demonstrably works — top-10 customer revenue has grown 6x over the last decade 2026-03 H1 FY26 interim.
  • Fortress balance sheet with genuine optionality. Net cash $17.5m, undrawn RCF $76m plus $100m accordion, capital reduction completed 7 Nov 2025 unlocked £284m of distributable reserves, $25m buyback announced. The CEO personally spent £326k in March 2026 exercising options and retaining shares 2026-03 director dealing. Board rejected £26.50/share in June 2025, currently 135% above the current price.
  • AI-enabled vertical SaaS optionality with proprietary data moat. 200m+ patient encounters, Microsoft Azure/AI partnership including Trisus Assist (>200 customers), extending into labour productivity and reimbursement intelligence. Value-per-seat can plausibly rise as AI agents automate more of the 340B/chargemaster workflow 2026-03 H1 FY26.

Key risks

  • 340B is a regulatory/political construct that is under manufacturer attack. The FY26 miss was caused by pharma manufacturers restricting 340B drug supply, slowing revenue recognition even though Craneware identifies the opportunities. HRSA rebate pilot was announced then postponed by court order — regulatory whipsaw is now a live risk to the largest recent growth driver 2026-07 FY26 trading update; 2026-01 H1 FY26 trading update.
  • Concentration in US healthcare with policy exposure. 100% US hospital revenue, USD reporting, GBP dividend. Changes to Medicare, 340B, or MFP rules could materially reshape addressable market. Not disclosed but inferred: dollar depreciation would reduce GBP fair value.
  • Growth stall risk becoming structural. ARR growth of 4% in H1 FY26 was already below the double-digit revenue targets, and FY26 revenue will now be flat. If enterprise contract deferrals ("small number of significant enterprise contracts... deferred") represent competitive losses rather than timing, ARR could roll over in FY27 2026-07 FY26 trading update.

Operating leverage

Craneware is a textbook high-operating-leverage SaaS business. Gross margin is 85% (H1 FY26: $89.7m gross profit on $105.7m revenue). Adjusted EBITDA margin has expanded from 30% (H1 FY25) to 32% (H1 FY26) on 6% revenue growth, demonstrating strong incremental margin. R&D at ~28% of revenue is the largest fixed-cost element ($29.8m H1 FY26), of which ~$8.4m is capitalised. Approximately 20% of the cost base is Sterling-denominated (UK employees); the majority is US dollar. Because the platform is built and scaled, an incremental $10m of revenue would likely drop through at 60-70% contribution margin, meaning a 10-20% revenue beat could plausibly add 40-60% to operating profit. Conversely — and this is what H1 FY26 to FY26 illustrates — a slowdown that leaves fixed costs unabsorbed compresses margins fast. The inflection is bidirectional. 2026-03 H1 FY26; 2025-09 FY25 results

Value-trap signals

  • Consecutive downward revisions to growth expectations. January 2026 trading update reiterated "line with market expectations"; March 2026 interims maintained confident tone; July 2026 warned FY26 would be broadly flat. Rapid credibility deterioration.
  • 340B business model faces manufacturer counter-attack. The very drug purchases that drive Craneware's Shelter revenue are being throttled by pharma companies restricting supply — this is a structural, not cyclical, dynamic that management cannot control.
  • Absence of new-customer growth historically. Expansion sales were 98% of new sales in H1 FY25; even after "improvement" to 12% new-customer share in H1 FY26, this reveals the underlying business is heavily dependent on cross-sell rather than share gains.

Earnings vs. expectations

The pattern across the period is: reliable delivery FY22-FY25, then a sharp miss in FY26. FY25 was flagged as ahead of expectations in the July 2025 trading update ("profitability ahead of consensus market expectations"). H1 FY26 (March 2026) was described as in line with expectations. The January 2026 trading update still guided to double-digit near-term growth and in-line FY26 delivery. Then on 3 July 2026 the company issued a downgrade: FY26 revenue $205-208m and EBITDA $65-67m — "below market expectations" and flat vs FY25 — driven by 340B conversion slowdown. So: string of in-line-to-beat prints for 3 years, followed by a material miss in the closing weeks of FY26. This is a first-strike credibility event, not a pattern of repeated misses.

Conviction

Conviction: 3 (moderate).

Anchors: (1) Clean, well-disclosed financials with a genuinely conservative Annuity-SaaS accounting model that recognises revenue over contract life — earnings quality is high. (2) Balance sheet strength is unambiguous (net cash, buyback authority, undrawn facilities). (3) The rejected £26.50 offer in mid-2025 provides a strategic-buyer floor, though at a different growth trajectory.

Caveats: (1) The FY26 downgrade fundamentally reset the growth narrative and I cannot confidently distinguish "timing" from "structural" until FY27 guidance is issued in September 2026. (2) 340B rule-making is exogenous and could plausibly deliver either upside (rebate pilot restored) or further downside (further supply restrictions) within a 12-month window; the range of outcomes is wide.

Driver scoring

  • ai_beneficiary = 45. Genuine proprietary data (200m encounters), Microsoft partnership, launched Trisus Assist. But AI is enhancement rather than primary demand driver — value flows through operational efficiencies rather than a new AI revenue line.
  • operating_leverage = 78. Pure vertical SaaS with 85% gross margin, largely fixed R&D cost base, and demonstrated margin expansion when growing (30%→32% H1 FY25 to H1 FY26). Constraint on higher score is that growth has stalled, capping realised leverage near-term.
  • earnings_surprise_trend = 40. Sequence of in-line prints then a material miss in FY26 breaks the record.
  • cyclicality = 25. Recurring SaaS with 90%+ retention, but the 340B revenue stream introduces regulatory volatility that behaves quasi-cyclically.
  • moat = 65. Genuine switching costs (Chargemaster is a chart-of-accounts equivalent for revenue), proprietary regulatory expertise, and unique dataset. Not 80+ because 340B faces regulatory challenge.
  • leverage = 15. Net cash of $17.5m, undrawn $176m of facility, fortress balance sheet.
  • earnings_quality = 75. Clean SaaS revenue recognition, high cash conversion (85% rolling 12m), amortisation of acquired intangibles well-disclosed as adjustment. Deferred income and cash-held-on-behalf-of-customers add some complexity but are transparently reported.
  • management_quality = 65. CEO Keith Neilson is founder-executive with 25+ years, personally increased stake to 9.05% in March 2026, rejected a takeover approach at 2.35x the current price. However, the January 2026 in-line reiteration followed six months later by a material miss raises questions on forecast discipline.
  • growth_momentum = 35. Just downgraded from double-digit to flat; ARR growth of 4% is well below reported revenue growth; enterprise contract deferrals into FY27 create uncertainty.

Overall score: 505

Craneware fits the investor profile as a partial-fit "known name at a fair price" rather than a top-band buy. Operating leverage is high, valuation now looks reasonable to modestly cheap, downside protection is strong (net cash, moated customer base, strategic-buyer interest at higher prices). What holds the score back: AI exposure is real but indirect (this is vertical SaaS that uses AI, not AI infrastructure), and growth momentum has just broken with a live regulatory overhang on the largest growth engine. Score reflects a stock worth owning at these levels but not one that should be a portfolio anchor.

Filings consulted · 40

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-03Fy26 Trading Update2026-07-03_9650668_fy26-trading-update.md0.85
  2. 2026-03-04Director 039 S Acquisition OF Shares2026-03-04_9456977_director-039-s-acquisition-of-shares.md0.75
  3. 2026-03-02Fy26 Interim Results2026-03-02_9452145_fy26-interim-results.md0.90
  4. 2026-01-20H1 Fy26 Trading Update And Notice OF Results2026-01-20_9367658_h1-fy26-trading-update-and-notice-of-results.md0.85
  5. 2025-11-21Result OF Agm2025-11-21_9250001_result-of-agm.md0.26
  6. 2025-11-21Agm Statement And Board Changes2025-11-21_9248226_agm-statement-and-board-changes.md0.34
  7. 2025-10-22Annual Report Notice OF Agm Directorate Change2025-10-22_9188009_annual-report-notice-of-agm-directorate-change.md0.81
  8. 2025-09-15Fy25 Final Results2025-09-15_9106955_fy25-final-results.md0.85
  9. 2025-08-20Result OF Agm2025-08-20_9066395_result-of-agm.md0.26
  10. 2025-07-16Fy25 Trading Update2025-07-16_8981215_fy25-trading-update.md0.55
  11. 2025-03-11Fy25 Interim Results2025-03-11_8772293_fy25-interim-results.md0.58
  12. 2025-01-13H1 Fy25 Trading Update2025-01-13_8684202_h1-fy25-trading-update.md0.55
  13. 2024-11-13Result OF Agm2024-11-13_8548094_result-of-agm.md0.20
  14. 2024-11-13Agm Statement And Board Changes2024-11-13_8546242_agm-statement-and-board-changes.md0.26
  15. 2024-10-16Posting OF Annual Report And Notice OF Agm2024-10-16_8490562_posting-of-annual-report-and-notice-of-agm.md0.62
  16. 2024-09-03Fy24 Final Results2024-09-03_8396015_fy24-final-results.md0.65
  17. 2024-07-18Fy24 Trading Update And Notice OF Results2024-07-18_8317424_fy24-trading-update-and-notice-of-results.md0.38
  18. 2024-03-04Interim Results2024-03-04_8067483_interim-results.md0.41
  19. 2024-01-17Trading Update And Notice OF Results2024-01-17_7992463_trading-update-and-notice-of-results.md0.38
  20. 2023-11-16Result OF Agm2023-11-16_7886560_result-of-agm.md0.14
  21. 2023-11-16Agm Statement2023-11-16_7884398_agm-statement.md0.18
  22. 2023-10-17Posting OF Annual Report And Notice OF Agm2023-10-17_7822474_posting-of-annual-report-and-notice-of-agm.md0.43
  23. 2023-09-05Final Results2023-09-05_7735263_final-results.md0.45
  24. 2023-07-17Fy23 Trading Update And Notice OF Results2023-07-17_7635562_fy23-trading-update-and-notice-of-results.md0.21
  25. 2023-03-06Interim Results2023-03-06_7323674_interim-results.md0.23
  26. 2023-01-19Trading Update And Notice OF Results2023-01-19_7469619_trading-update-and-notice-of-results.md0.21
  27. 2022-11-15Result OF Agm2022-11-15_7373840_result-of-agm.md0.07
  28. 2022-11-15Agm Statement And Board Appointment2022-11-15_7372275_agm-statement-and-board-appointment.md0.10
  29. 2022-10-14Posting OF Annual Report And Notice OF Agm2022-10-14_7349126_posting-of-annual-report-and-notice-of-agm.md0.24
  30. 2022-09-20Final Results2022-09-20_7369421_final-results.md0.25
  31. 2022-09-14Change OF Date OF Final Results2022-09-14_7315825_change-of-date-of-final-results.md0.25
  32. 2022-07-26Fy22 Trading Update And Notice OF Results2022-07-26_7136127_fy22-trading-update-and-notice-of-results.md0.21
  33. 2022-03-14Interim Results2022-03-14_6896717_interim-results.md0.23
  34. 2022-01-31Trading Update And Notice OF Results2022-01-31_7000279_trading-update-and-notice-of-results.md0.21
  35. 2021-11-16Result OF Agm2021-11-16_6788325_result-of-agm.md0.07
  36. 2021-11-16Agm Statement And Integration Update2021-11-16_6739486_agm-statement-and-integration-update.md0.10
  37. 2021-10-19Posting OF Annual Report And Notice OF Agm2021-10-19_6816763_posting-of-annual-report-and-notice-of-agm.md0.24
  38. 2021-09-21Final Results2021-09-21_6512425_final-results.md0.25
  39. 2021-07-13Trading Update And Notice OF Results2021-07-13_6612848_trading-update-and-notice-of-results.md0.09
  40. 2021-07-13Completion OF Sds Holdco Inc Acquisition2021-07-13_6612858_completion-of-sds-holdco-inc-acquisition.md0.07

This research note was authored by a large language model after reading 33 regulatory filings published between 2021-07-13 and 2026-07-03. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.